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Abstract
Background/Aims: Thalassaemia accompanied with iron-overload is common in Hong Kong. 
Iron-overload induced cardiomyopathy is the commonest cause of morbidity and mortality 
in patients with β-thalassaemia. Chronic iron-overload due to blood transfusion can cause 
cardiac failure. Decreased antioxidant defence and increased ROS production may lead to 
oxidative stress and cell injury. Iron-overload may lead to heart tissue damage through lipid 
peroxidation in response to oxidative stress, and a great diversity of toxic aldehydes are 
formed when lipid hydroperoxides break down in heart and plasma. Methods: Iron entry into 
embryonic heart H9C2 cells was determined by calcein assay using a fluorometer. Reactive 
oxygen species (ROS) production in cells treated with FeCl3 or thrombopoietin (TPO) was 
monitored by using the fluorescent probe H2DCFDA. Changes in mitochondrial membrane 
potential of H9C2 cells were quantified by using flow cytometry. Results: We demonstrated 
that iron induced oxidative stress and apoptosis in cardiomyocytes, and that  iron increased 
ROS production and reduced cell viability in a dose-dependent manner. Iron treatment 
increased the proportion of cells with JC-1 monomers, indicating a trend of drop in the 
mitochondrial membrane potential. TPO exerted a cardio-protective effect on iron-induced 
apoptosis. Conclusions: These findings suggest that iron-overload leads to the generation of 
ROS and further induces apoptosis in cardiomyocytes via mitochondrial pathways. TPO might 
exert a protective effect on iron-overload induced apoptosis via inhibiting oxidative stress and 
suppressing the mitochondrial pathways in cardiomyocytes.
D
ow
nl
oa
de
d 
by
: 
19
8.
14
3.
53
.1
 - 
9/
24
/2
01
5 
8:
44
:2
2 
AM
Cell Physiol Biochem 2015;36:2063-2071
DOI: 10.1159/000430173
Published online: July 17, 2015
© 2015 S. Karger AG, Basel
www.karger.com/cpb 2064
Chan et al.: Thrombopoietin Protects Cardiomyocytes
Cellular Physiology 
and Biochemistry
IntroductionThalassaemia accompanied with iron-overload is common in Hong Kong. Iron-overload induced cardiomyopathy is the commonest cause of morbidity and mortality in patients with -thalassaemia. Chronic iron-overload due to blood transfusion can cause cardiac failure. It has been reported that iron-overload can cause toxic effect on heart, bone and nerve cells.Iron-overload may induce apoptosis in cardiomyocytes, and thrombopoietin (TPO) may exert a protective effect on this toxicity [1, 2]. In-vivo studies showed that iron-overload can cause eccentric cardiac hypertrophy, impairing cardiac output and exercise capacity [3, 4]. It is known that free radical species are important for biological functions. Excessive free radical species can induce tissue damage by disrupting lipids, DNA and proteins, leading to severe oxidative damage to cells [5]. Excess iron induced the over-production of superoxide (O2−) and hydroxyl (OH-) radicals via Fenton and Haber-Weis reactions, leading to cellular damage [5-7]. Decreased antioxidant defence and increased ROS production may lead to oxidative stress and cell injury. Iron-overload may lead to heart tissue damage through lipid peroxidation in response to oxidative stress, and a great diversity of toxic aldehydes are formed when lipid hydroperoxides break down in heart and plasma [8, 9]. These agents are associated with toxic effects on intracellular organelles, and then cause either apoptotic or necrotic cell death [10]. There are many sources of ROS, including mitochondria, xanthine oxidase, uncoupled nitric oxide synthases and NADPH oxidases, all of them contribute to the development of cardiomyocyte hypertrophy [11].Thrombopoietin (TPO), the c-Mpl ligand, is the primary physiologic regulator of megakaryocyte and platelet development. It can also protect CD34+ cells and megakaryocytes from undergoing apoptosis [12, 13]. It has been shown that the production of ROS during the oxidative stress response could cause cardiomyocyte apoptosis, [14] playing an important role in ischemic heart disease, and cardiac failure [15]. Thus, in this study, we investigated iron exposure induced oxidative stress and its relation to cardiomyocyte apoptosis. The protective effect of TPO and its mechanism on iron induced cardiotoxicity were also investigated.
Materials and Methods
H9C2 cellsEmbryonic H9C2 cells (American Type Tissue Collection, Manassas, Va) were cultured in IMDM or DMEM supplemented with 10% fetal calf serum in a 5% CO2 incubator at 37°C. All media and culture reagents were purchased from Gibco (Grand Island, NY). For oxidative stress analysis, H9C2 cells were seeded in 96 well plates at 5x103 cells per well for 24 hours. For apoptosis analysis, H9C2 cells were seeded in 6 well plates at 2x105 cells per well for 24 hours. Then, cells were incubated with FeCl3 (Sigma) or TPO (50 ng/ml [1], R&D) for a further 72 hours.
Monitoring iron entry into H9C2 cellsH9C2 cells were exposed to 2.5 uM calcein green (Molecular Probes, Eugene, OR) in DMEM containing 10 mM Na-HEPES (N-2-hydroxyethylpiperazine-N_-2-ethanesulfonic acid) and 1 mg/mL bovine serum albumin for 10 minutes at 37°C , and washed with preheated HEPES-buffered saline (HBS, pH 7.4). Then, the cells were exposed to FeCl3 (0.15 mM) in HBS containing 0.5 mM probenecid for 50 minutes at 37°C. 
Probenecid was added  to prevent leakage of the anionic fluorescent probes from cells [14]. To observe the chelating effect, an intracellular iron chelator, ICL 670 was obtained from Roche. One hundred microliters 
of stock solution was added to each culture at five minutes intervals to give final concentrations of 0.2, 0.6, 
1.0, 1.4 and 1.8 mM ICL670. The fluorescence was measured at an excitation wavelength of 485 nm and an 
emission wavelength of 538 nm using a fluorometer (Fusion, α-FP).
Measurement of Oxidative Stress using 2,7-dichlorodihydrofluorescein diacetate (H2DCF-DA) fluorescence 
assayROS production in cells treated with FeCl3 or TPO was monitored by using H2DCFDA as fluorescent probe (Sigma); once inside the cell, H2DCFDA is deacetylated by intracellular esterases to become H2DCFH. It can 
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be converted by hydrogen peroxides and hydroxyl radicals in cells to fluorescent 2’,7’-dichlorofluorescein (DCF). H9C2 cells were resuspended in DMEM with 2% FCS. FeCl3 (0.075-0.6 mM), or FeCl3 (0.3 mM) with/without TPO (50 ng/ml) was added to the cells for 24 hours, respectively. Then, the cells were treated 
with H2DCF-DA (5 uM) in phosphate buffered saline at 37°C. DCF fluorescence produced by the cells was continuously measured up to 160 minutes or four hours at an excitation wavelength of 485 nm and an 
emission wavelength of 538 nm using a fluorometer.
Detection of apoptosis, and mitochondrial membrane potential in H9C2 cells treated with FeCl3 and TPO 
by using flow cytometryH9C2 cells were cultured in IMDM supplemented with 10% FCS. To investigate the apoptotic effect of FeCl3, cells were resuspended in IMDM with 2% FCS, and then incubated with FeCl3 (0.0375 mM to 0.6 mM), or FeCl3 (0.3 mM) with/without TPO for 72 hours. Then, the cells were stained with Trypan blue and observed under microscope, and stained with Annexin V/PI or anti-active caspase-3/FITC antibody (BD 
Biosciences, San Diego) and analyzed by suing flow cytometry, respectively.To investigate the mitochondrial membrane potential changed in H9C2 cells treated with FeCl3 and TPO, cells were resuspended in IMDM with 2% FCS, and then incubated with FeCl3 (0.3 mM) with/without TPO for 72 hours, and then were stained with JC-1 (5, 5', 6, 6'-tetrachloro-1, 1',3, 3' 
Tetraethylbenzimidazolcarbocyanine iodide) (BD Biosciences, San Diego) and analyzed by using flow cytometry.Ten thousand events were acquired for each sample and analyzed by WinMDI2.8 software.
Statistical analysis
The mean and SEM were computed for each treatment group. Statistical significant differences among 
treatment groups and control group were detected by the One Way Anova Test with Turkey’s Multiple Comparison Test for all pairwise multiple comparisons (Glantz SA. Primer of biostatistics, 3rd Edition., New York: McGraw Hill; 1992.). A P value of less than 0.05 was considered to be statistically significant. Three 
levels of significance were denoted as: *: P<0.05, **: P<0.01, and ***: P <0.001.
Results
Iron entry into cardiomyocytes 
H9C2 cells were stained with calcein green with high fluorescent signal and then incubated with FeCl3 (0.15 mM) at 37°C (Fig. 1). The intracellular calcein green fluorescence signal was quenched by FeCl3 and reached a steady state after 50 minutes (Fig. 1). Upon 
subsequent addition of ICL670, an intracellular iron chelator, the intracellular fluorescence signal underwent a dose-dependent restoration (Fig. 1), indicating that the previous 
quenching was specifically due to Fe3+entry.
Fig. 1. Monitoring iron entry into cardi-omyocytes. H9C2 cells labeled with calcein green were exposed to FeCl3 (0.15 mM) for 50 minutes. ICL 670 was added at 5-minute 
intervals to give final concentrations of 0.2, 0.6, 1.0, 1.4 and 1.8 mM. All reactions were 
carried out at 37°C. The average fluorescen-ce was shown in the Figure (Cells treated with ICL 670 at indicated concentration and time was denoted with an arrow).
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Iron induced ROS production on cardiomyocytesThe effect of FeCl3 on ROS production of H9C2 cell cultures was analyzed (Fig. 2A). A FeCl3 concentration of 0.075 mM was sufficient to induce high levels of ROS in cell cultures. 
Fig. 2. Time course of ROS producti-on. (A) H9C2 cells were treated with increasing concentrations of FeCl3 (0.075-0.6 mM) for 24 hours. After 
H2DCF-DA staining, DCF fluorescence produced by the cells was continuously measured for up to 160 minutes (N=3, various concentrations of FeCl3 vs. 
control group, ***P<0.001). (B) H9C2 cells were treated with 0.3 mM FeCl3 with or without TPO for 24 hours. After 
H2DCF-DA staining, DCF fluorescence produced by the cells was continuously measured for up to 240 minutes (N=3, 
FeCl3 vs. FeCl3+TPO group, ***P<0.001; 
TPO vs. control group * P<0.05).
Fig. 3. Apoptotic effects of FeCl3 on H9C2 cells. (A) To investigate the apoptotic effect of FeCl3, H9C2 cells were resuspended in serum depleted IMDM medium, and then incubated with different concentrations of FeCl3 (0.0375mM to 0.60mM) for 72 hours. (A) Samples were investigated under 
microscope using high-power (*200) objective. Compared to the normal control group, the number of non-ad-herent cells increased in a dose-de-pendent manner. (B) Viability of H9C2 cells were investigated by Trypan Blue Count. The cell viability were decrea-sed in dose-dependent manner (N=6, FeCl3 vs. control group, **P<0.01).
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With increasing concentrations of FeCl3 (0.075-0.6 mM), the levels of ROS in cell cultures 
were significantly increased (Fig. 2A).
TPO reduced ROS production from iron-overload cardiomyocytesThe ability of TPO to attenuate intracellular ROS production was assessed in H9C2 cells. The cells were treated with FeCl3 (0.3 mM) with or without TPO (50 ng/ml) for 24 hours 
(Fig. 2B). TPO significantly decreased the FeCl3-induced ROS production, and not changed 
Fig. 4. FeCl3-treated H9C2 cells were stained with AnnexinV/FITC and pro-pidium iodide (PI), and then examined 
by flow cytometry. Density plot analy-sis demonstrated that early apoptotic cells (Annexin V positive, PI negative, R2), late apoptotic and necrotic cell (Annexin V positive, PI positive, R1), and total dead cells (R1 + R2) were increased in culture cells treated with FeCl3 (R1, R2 and R1+R2, N=6, FeCl3 
vs. control group, *P<0.05, **P<0.01 
and ***P<0.001).
Fig. 5. FeCl3/TPO-treated H9C2 cells were stained with AnnexinV/FITC and propidium iodide (PI), and then 
examined by flow cytometry. Early apoptotic cells (Annexin V positive, PI negative, R2), late apoptotic and necrotic cell (Annexin V positive, PI positive, R1), and total dead cells (R1 + R2) were increased in FeCl3 treated cells (R1, R2 and R1+R2, n=6, FeCl3 
vs.control group, ***P<0.001). TPO 
significantly reduced the proportion of late apoptotic and necrotic cells (R1) (n=6, TPO+FeCl3 vs. FeCl3 group, 
*P<0.05) as well as total dead cells (R1+R2) (n=6, TPO+FeCl3 vs. FeCl3 
group, *P<0.05).
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the baseline level of ROS production in H9C2 cells (Fig. 2B). It was suggested that TPO was effective in reducing the ROS production induced by iron-overload.
Iron-induced apoptosis in Cardiomyocytes was rescued by TPO Results of trypan blue assay on H9C2 cells demonstrated that FeCl3 (0-0.6 mM, 72 hours) 
significantly reduced cell viability in a dose-dependent manner (n=6)  (Fig. 3). These results 
were also confirmed by flow cytometry with Annexin V/PI double staining. Early apoptotic cells (R2) and total dead cells (R1+R2) were significantly increased in FeCl3-treated H9C2 cells in a dose-dependent manner (Fig. 4). Apoptosis assays were also performed to elucidate whether TPO has anti-apoptotic potential on FeCl3-treated H9C2 cells (Fig. 5). Compared to the normal control group, FeCl3-treated cells showed a marked increase in the proportions of early apoptotic cells (R2), late 
apoptotic and necrotic cell (R1) and total dead cells (R1+R2), and it was significantly reduced 
by TPO (*P<0.05; n=6) (Fig. 5), while TPO alone had no noticeable effect on apoptosis of H9C2 cells, suggesting TPO has an anti-apoptotic effect on H9C2 cells treated with FeCl3.Caspase-3, which is an effector protein of the caspase family, plays an essential role in apoptosis. Levels of active caspase-3 in FeCl3-treated group were significantly increased, compared with control group (n=6, P<0.001). Treatment with TPO with FeCl3 significantly decreased caspase-3 expression, compared with FeCl3-treated group (Fig. 6), suggesting a protective effect of TPO on FeCl3 treated cells.JC-1 can be rapidly taken up into mitochondria by the polarized mitochondrial membrane potential to form JC-1 aggregates in living cells. Depolarization of mitochondrial 
membrane potential indicates altered mitochondrial function. JC-1 fluorescence in these apoptotic cells does not accumulate in mitochondria and remains as monomers (R2). There are transitional subset of apoptotic cells (R1) containing both monomers and aggregates. Our data showed that the proportion of cells containing both JC-1 monomers and aggregates 
(R1), or JC-1 monomers (R2) increased significantly in FeCl3-treated cells, compared with normal control cells (n=6, P<0.001) (Fig. 7), indicating a drop in mitochondrial membrane potential and an increase in the proportion of apoptotic cells. Additional treatment with TPO 
significantly elevated the mitochondrial membrane potential and reduced the population of apoptotic cells, compared with the FeCl3-treated group  (Fig. 7). It was suggested that 
Fig. 6. H9C2 cells under different treat-ments were stained with anti-active Caspa-se-3/FITC antibody. The expression of acti-
ve caspase-3 increased significantly in FeCl3 treated H9C2 cells (n=6, FeCl3 vs. control 
group, ***P<0.001). Moreover, TPO signifi-cantly reduced the expression of caspase-3 of FeCl3-treated cells (n=6, TPO+FeCl3 vs. 
FeCl3 group, *P<0.05).
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TPO has an anti-apoptotic effect on iron-overload induced apoptosis via suppressing the mitochondrial pathways in H9C2 cells.
DiscussionTransfusion iron-overload associated with thalassemia leads to the appearance of non-transferrin-bound iron (NTBI) in blood that is toxic and causes morbidity and mortality via tissue damage [16]. Fe3+ is the common form of iron in the blood circulation of iron-overload patients. In this study, we designed an in vitro iron-overload model to study the apoptotic effect of FeCl3 and the anti-apoptotic effect of TPO on cardiomyocytes. In conclusion, we demonstrated that the protective effects of TPO on iron-induced cardiomyocytes injury in 
vitro, and that this effect was likely to be mediated by reduced ROS production and inhibited anti-apoptotic activity. The inhibition of oxidative stress and apoptosis by TPO might play an important role in the cardiocyte protection.Our results demonstrated that FeCl3 could penetrate H9C2 cells to quench intracellular 
calcein green fluorescence. ICL670 is a cell-permeating and efficient iron chelator which is highly selective for iron as Fe3+ [15, 17]. It can restore fluorescence by removing the cytosolic iron complexed to calcein green in cell systems, thus we used it in order to generate the 
high unquenching level. Upon subsequent addition of ICL670, the intracellular fluorescence 
underwent a dose-dependent restoration. It further confirmed the iron entry into cardiomyocytes.Activation of mitochondria mediated apoptotic pathway could induce the cardiomyocytes apoptosis [18]. Inhibiton of ROS production could protect cardiomyocytes against 
oxidative stress [19]. According to our data, iron significantly increased ROS production in cardiomyocytes and induced cells apoptosis by activation of mitochondria mediated 
apoptotic pathway. TPO significantly attenuated ROS production, inhibited collapse of mitochondrial membrane potential, attenuated the expression of active caspse-3, and finally 
Fig. 7. Mitochondrial membrane potential changed in H9C2 cells treated with FeCl3 and TPO. Cells under different treatments were stained with JC-1 reagent. The proportion of apoptotic cells contains JC-1 monomers (R2), and a transitional subset of cells con-tains both monomers and aggregates (R1). 
The apoptotic cells increased significantly in FeCl3-treated group (R1, R2 and R1+R2, n=6, 
FeCl3 vs. Control group, ***P<0.001). And reduced damage in the FeCl3+TPO group (R1, R2 and R1+R2, n=6, TPO vs. TPO+FeCl3 
group, **P<0.01, ***P<0.001).
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decreased apoptosis in iron-treated cardiomyocyte. Therefore, our data suggest that TPO inhibits apoptosis by suppressing oxidative stress abd inhibiting mitochondria mediated apoptotic pathway. Recently, it has been shown that TPO may induce PI3K/Akt-dependent eNOS phosphorylation and nitric oxide (NO) release in both cardiac [20] and endothelial cells [21]. As far as is known, NO plays important role in cell damage and apoptosis [22]. Thus, the PI3K/Akt-NO pathway was the possible mechanism reponsible for the anti-oxidative activity of TPO, it would be further investigated. In addtion, the impairment of membrane proteins might prevent the adaptation of cardiomyocytes to intermittent hypoxia [23].It is known that TPO is the most potent thrombopoietic factor. The second generation thrombopoietic agents, such as TPO peptide mimetics: Romiplostim (AMG 531) and TPO nonpeptide mimetics: Eltrombopag (SB497115, Promacta) have been used to treat patients with thrombocytopenia and the treatment has been suggested to be effective and safe [24, 25]. Recently, we demonstrated that TPO is not only a thrombopoietic agent, but also plays an important role in non-hematopoietic systems, for example, the cardiovascular system. TPO (50 ng/ml and 100 ng/ml) protected cardiomyocytes from doxorubicin-induced injury [1]. In this study, 50 ng/ml TPO was used to treat the cardiomyocytes apoptosis induced by 
iron-overload. Our group is the first to use TPO as a protective drug to treat iron-overload-induced cardiomyocytes apoptosis. We demonstrated a high potential for this drug in managing iron-overload-induced cardiomyopathy in thalassemia patients.
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